These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19804613)

  • 1. Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.
    Wicha MS
    Breast Cancer Res; 2009; 11(5):108. PubMed ID: 19804613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.
    Puppe J; Drost R; Liu X; Joosse SA; Evers B; Cornelissen-Steijger P; Nederlof P; Yu Q; Jonkers J; van Lohuizen M; Pietersen AM
    Breast Cancer Res; 2009; 11(4):R63. PubMed ID: 19709408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
    Henneman L; van Miltenburg MH; Michalak EM; Braumuller TM; Jaspers JE; Drenth AP; de Korte-Grimmerink R; Gogola E; Szuhai K; Schlicker A; Bin Ali R; Pritchard C; Huijbers IJ; Berns A; Rottenberg S; Jonkers J
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8409-14. PubMed ID: 26100884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Ratz L; Brambillasca C; Bartke L; Huetzen MA; Goergens J; Leidecker O; Jachimowicz RD; van de Ven M; Proost N; Siteur B; de Korte-Grimmerink R; Bouwman P; Pulver EM; de Bruijn R; Isensee J; Hucho T; Pandey G; van Lohuizen M; Mallmann P; Reinhardt HC; Jonkers J; Puppe J
    Breast Cancer Res; 2022 Jun; 24(1):41. PubMed ID: 35715861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
    Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducing synthetic lethality using PARP inhibitors.
    Boss DS; Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
    Lim KS; Li H; Roberts EA; Gaudiano EF; Clairmont C; Sambel LA; Ponnienselvan K; Liu JC; Yang C; Kozono D; Parmar K; Yusufzai T; Zheng N; D'Andrea AD
    Mol Cell; 2018 Dec; 72(6):925-941.e4. PubMed ID: 30576655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
    Alli E; Sharma VB; Sunderesakumar P; Ford JM
    Cancer Res; 2009 Apr; 69(8):3589-96. PubMed ID: 19351835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
    Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
    Zhang D; Baldwin P; Leal AS; Carapellucci S; Sridhar S; Liby KT
    Theranostics; 2019; 9(21):6224-6238. PubMed ID: 31534547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.
    Gonzalez ME; Li X; Toy K; DuPrie M; Ventura AC; Banerjee M; Ljungman M; Merajver SD; Kleer CG
    Oncogene; 2009 Feb; 28(6):843-53. PubMed ID: 19079346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
    Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
    J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
    Zhang H; Yu N; Chen Y; Yan K; Wang X
    J Cell Biochem; 2019 Aug; 120(8):13037-13045. PubMed ID: 30873673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
    Wu J; Crowe DL
    Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
    Rondinelli B; Gogola E; Yücel H; Duarte AA; van de Ven M; van der Sluijs R; Konstantinopoulos PA; Jonkers J; Ceccaldi R; Rottenberg S; D'Andrea AD
    Nat Cell Biol; 2017 Nov; 19(11):1371-1378. PubMed ID: 29035360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer.
    Bae WK; Hennighausen L
    Mol Cell Endocrinol; 2014 Jan; 382(1):593-597. PubMed ID: 23684884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
    Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.